Results 21 to 30 of about 3,108,169 (356)
Biomedicines, 2022 Real-world evidence plays an important role in the assessment of efficacy and safety of novel therapies. The increasing use of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma has led to notably improved clinical outcomes, while ...
Daniella Kuzmanovszki +13 more
doaj +1 more source
Biology of advanced uveal melanoma and next steps for clinical therapeutics [PDF]
, 2014 Uveal melanoma is the most common intraocular malignancy although it is a rare subset of all melanomas. Uveal melanoma has distinct biology relative to cutaneous melanoma, with widely divergent patient outcomes.
Bastian, BC +17 more
core +1 more source
Treatment of Advanced Metastatic Melanoma
Dermatology Practical & Conceptual, 2021 The introduction in clinical practice of new drug compounds both targeted therapies anti-BRAF and checkpoint inhibitors have largely improved our potential to manage advanced metastatic melanoma patients. This has led to a significant improvement in terms of response rates and particularly in the overall survival (OS).
Quaglino, Pietro +5 more
openaire +4 more sources
Frontiers in Oncology, 2018 Antibodies against programmed cell death protein 1, such as nivolumab and pembrolizumab, are widely used for treating various cancers, including advanced melanoma.
Taku Fujimura +21 more
doaj +1 more source
Novel nano-biosensors for life science systems and their applications in early, accurate, and non-invasive melanoma and other types of cancer detection [PDF]
, 2007 Melanoma (the 5th and 6th most common cancer in Caucasian males and females, respectively), is the most severe form of skin cancer, which is often fatal if recognized in its advanced stage.
Bockrath, Marc +2 more
core +1 more source
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
New England Journal of Medicine, 2019 BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. We now report 5-year outcomes in the trial. METHODS We randomly
J. Larkin +30 more
semanticscholar +1 more source
Frontiers in Medicine, 2019 Ipilimumab, in combination with nivolumab, is one of the promising drugs that enhance the anti-tumor immune response of patients with advanced melanoma. Since the co-administration of nivolumab with ipilimumab in the neoadjuvant setting expands melanoma ...
Taku Fujimura +7 more
doaj +1 more source
Understanding signaling cascades in melanoma [PDF]
, 2008 Understanding regulatory pathways involved in melanoma development and progression has advanced significantly in recent years. It is now appreciated that melanoma is the result of complex changes in multiple signaling pathways that affect growth control,
Akslen L. A. +58 more
core +1 more source
Advances in Targeting Cutaneous Melanoma [PDF]
Cancers, 2021 To date, the skin remains the most common cancer site among Caucasians in the western world. The complex, layered structure of human skin harbors a heterogenous population of specialized cells. Each cell type residing in the skin potentially gives rise to a variety of cancers, including non-melanoma skin cancer, sarcoma, and cutaneous melanoma ...
Dimitri Kasakovski +3 more
openaire +2 more sources
SCD5 restored expression favors differentiation and epithelial-mesenchymal reversion in advanced melanoma [PDF]
, 2018 Our previous data supported a role for the Stearoyl-CoA desaturase (SCD5) in protection against malignancy, whereby it appears to functionally modify tumor stroma impairing tumor spread.
Bellenghi, Maria +8 more
core +1 more source